B cell drug set to enter phase III testing
March 30, 2011…takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips
Dalfampridine may improve walking ability: phase III results
March 9, 2011…A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
Mirtazapine, paroxetine associated with greater risk of weight gain
March 9, 2011The first meta-analysis of the effect of antidepressants on body weight has found that mirtazapine, paroxetine and amitriptyline are associated with a greater risk of weight gain (Serretti & Mandelli. J Clin Psychiatry 2010; 71: 1259-1272). Fluoxetine and bupropion were associated with some weight loss. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter wi…
White matter hyperintensities predict cognitive decline
February 23, 2011…White matter hyperintensities are a predictor of cognitive decline in relatively healthy older subjects, according to data from the Alzheimer Disease Neuroimaging Initiative (Carmichael et al. Arch Neurol 2010; 67: 1370-1378). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
MoCA recommended to detect cognitive dysfunction in Parkinson’s disease
February 23, 2011…of the Parkinson Study Group Cognitive/Psychiatric Working Group has recommended the Montreal Cognitive Assessment (MoCA) as the most suitable tool to detect mild cognitive impairment (MCI) in patients with Parkinson’s disease (Chou et al. Mov Disord 2010; 25: 2501-2507). The task force further recommended that the MoCA be employed in clinical trials of PD where the primary outcome is not cognitive performance. Subscribe to read more It takes 30…